TABLE 4.

Characteristics of fecal calprotectin monitoring studies

Study	FC assay	Upper limit of normal range (in μg/g)	Basis of relapse diagnosis	Pretest probability of relapse	Post-test probability of relapse		Time between drift out of normal range to relapse	N per 100 patients
					when upward trend in FC out of normal range (95% CI)	when consecutive values in normal range (95% CI)		True Positives	True Negatives	False Positives	False Negatives
Dabritz 201323	Immunodiagnostic	15	C	34%	63% (55 to 71%)	12% (8 to 19%)	2–3 months	27	51	15	7
De Vos 201328	PhiCal	300*	C&E	33%	83% (61 to 94%)	20% (15 to 27%)	3 months	17	63	4	16
Jauregui-Amazega 201427	Cerba internacional	250	E	27%	53% (33 to 73%)	18% (12 to 26%)	3 months	13	62	11	14
Lasson 201526 **	Buhlmann	300	C	50%	57% (47 to 67%)	33% (15 to 58%)	Unknown	40	20	30	10
Molander 201525	Calpro	200	E	31%	57% (36 to 76%)	20% (12 to 30%)	2–4 months	17	57	12	14
Yamamoto 201524	Canton	55	E	30%	66% (52 to 77%)	6% (2 to 16%)	2 months	26	56	14	4

Abbreviations: CI: confidence interval; C: relapse defined as clinical relapse; E: relapse defined as endoscopic relapse; C&E: relapse defined as both clinical relapse or endoscopic relapse.

^*FC value above cut-off in two consecutive months.

^**Only control group included in this table.